Mobile navigation menu modal
As cell and gene therapies (CGTs) continue to enter the market, treatment centers have become the primary gatekeepers...
Free drug removes price barriers, but Otarmeni shows why specialty therapy access still depends on PSPs, payers, and logistics.
How CGT manufacturers can reduce financial risk and reimbursement burden for treatment centers adopting commercial therapies.
How CGT manufacturers can reduce treatment center burden through better workflows, training, logistics, and system integration.
Overcome CGT capacity challenges with strategies for forecasting, staffing, and treatment center partnerships.
PURE Engagement: OBBBA Medicaid shifts may raise coverage churn, provider risk, and affordability pressures—forcing pharma to rethink market access.
How biopharma can transition patient support vendors while minimizing disruption and improving the patient and provider experience.
Nuvera’s people-first culture thrives on connection, empowerment, and joy.
Meet Srilekha: A global explorer using cultural insight to design impactful, patient-centered solutions at Nuvera.
Discover how Chaitanya, Data Consultant at Nuvera, channels his passion for healthcare into patient-first strategies in the PURE Engagement program.
Nuvera and P4 connected at Topgolf, blending teamwork, fun, and collaboration—a powerful reminder that strong teams create great outcomes.
Discover how PURE Engagement transforms patient support programs to improve adherence, HCP engagement, and long-term health outcomes.
We create effective treatment experience strategies through experience and market insights.
